Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

What is your preferred treatment for refractory warm autoimmune hemolytic anemia with autoimmune neutropenia?

2 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

For immunomodulation, have you trialed IVIG? If not, this would be worth a trial. For immunosuppression, I prefer to utilize a more T cell-directed agent after failure of steroids/rituximab. Thus, a trial of MMF or cyclophosphamide may be reasonable. I think MMF may take too long to work in a situat...

Would you offer radiation for a plasmacytoma found on piecemeal endoscopic resection of an initially presumed nasal polyp if subsequent PET/CT was negative and no surgical margin status was known?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

In general, unless an oncologic procedure was performed to address a solitary plasmacytoma, I would recommend a course of RT. For a lesion removed piecemeal, the risk of residual microscopic disease is quite high. As the lesion was small and only microscopic disease (presumably) remains, given the n...

Would you consider first line osimertinib to patients with an EGFR Exon 18 G719X mutation?

4
2 Answers

Mednet Member
Mednet Member
Medical Oncology · UCSD Moores Cancer Center

Yes, there is some retrospective data that osi (or afatinib) are reasonable options here

Would you offer adjuvant chemotherapy for MSI-H Stage II colon cancer with multiple high risk features?

5
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University College of Physicians and Surgeons

About 15-20% of colorectal cancers are found to be MSI-high. These tumors are generally associated with a superior prognosis to those who are MSI-stable. Thus, the question as to whether one should utilize adjuvant chemotherapy in the context of patients with stage II disease, a setting where adjuva...

What does bevacizumab contribute in metastatic cervical cancer when used in combination with a platinum doublet + pembrolizumab?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Cooper Medical School of Rowan University

I'm not sure how to answer the question. GOG 240 established paclitaxel/carboplatin/bevacizumab as the standard for first-line therapy for metastatic or recurrent cervical cancer.The BEATcc trial was a subsequent phase III trial for stage IVB, recurrent or metastatic cervical cancer that randomized ...

How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?

4
2 Answers

Mednet Member
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida

I would present or refer her case to a multidisciplinary tumor board to 1) review her MRI to confirm there is progression vs. therapy changes, 2) see if she is a candidate for resection or irradiation of the progressing lesion (possibly using bevacizumab to reduce risk of radiation necrosis), and 3)...

How do you discuss harms of MGUS screening with other medical providers?

7
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

I understand the intent of the question, but - as always - real life is more complicated. I agree that the evidence for screening completely healthy patients for MGUS does not currently exist. But, for patients with unexplained pertinent lab/imaging findings or symptoms, it's not unreasonable. In th...

How do you discuss harms of MGUS screening with other medical providers?

7
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

I understand the intent of the question, but - as always - real life is more complicated. I agree that the evidence for screening completely healthy patients for MGUS does not currently exist. But, for patients with unexplained pertinent lab/imaging findings or symptoms, it's not unreasonable. In th...

Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Langerhans cell histiocytosis (LCH) is a clonal proliferation of Langerhans cells (dendritic cells), part of the mononuclear-phagocytic system. Some patients present with unifocal disease, often in bone. A variety of treatments are acceptable for unifocal disease, including radiation therapy. Very l...

Would you give adjuvant chemo for a mucinous stage II adenocarcinoma of the colon in the lack of other high-risk clinical pathological features?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic

The mucinous feature is reported to be a poor prognostic feature in colorectal cancer based on some retrospective series (e.g., Symonds and Vickery, PMID 177180, Green et al., PMID 8380140, Catalano et al., PMID 21531784, and Ott et al., PMID 29870979). However, there are some other studies suggesti...